(Q38154038)

29 August 2017

Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies (English)

1 reference

29 August 2017

1 reference

2

Quentin J Sattentau

1 reference

29 August 2017

Torben Schiffner

1

1 reference

PubMed ID

24140477

29 August 2017

Christopher J A Duncan

series ordinal

3

1 reference

PubMed ID

24140477

29 August 2017

language of work or name

English

0 references

publication date

17 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

31

1 reference

29 August 2017

49

1 reference

29 August 2017

5789-5797

1 reference

A Blueprint for HIV Vaccine Discovery

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Development of prophylactic vaccines against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Molecular architecture of native HIV-1 gp120 trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Broad neutralization coverage of HIV by multiple highly potent antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Structural definition of a conserved neutralization epitope on HIV-1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Redefining the viral reservoirs that prevent HIV-1 eradication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Avoiding the void: cell-to-cell spread of human viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Recruitment of HIV and its receptors to dendritic cell-T cell junctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

The HTLV-1 Virological Synapse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Cell-to-Cell Spread of Retroviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

HIV-infected T cells are migratory vehicles for viral dissemination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

In vivo imaging of virological synapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Targeting early infection to prevent HIV-1 mucosal transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Virus cell-to-cell transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

HIV-1 Virological Synapse is not Simply a Copycat of the Immunological Synapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Cell-to-cell HIV-1 spread and its implications for immune evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Inefficient human immunodeficiency virus replication in mobile lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Dendritic Cells and HIV-1 Trans-Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Endocytosis of HIV: anything goes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Cell-to-cell transfer of HIV-1 via virological synapses leads to endosomal virion maturation that activates viral membrane fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Quantitative 3D video microscopy of HIV transfer across T cell virological synapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

The infectious synapse formed between mature dendritic cells and CD4(+) T cells is independent of the presence of the HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Follicular dendritic cells and human immunodeficiency virus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Maturation-induced cloaking of neutralization epitopes on HIV-1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Multiploid inheritance of HIV-1 during cell-to-cell infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Multiple proviral integration events after virological synapse-mediated HIV-1 spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Antiretroviral agents effectively block HIV replication after cell-to-cell transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Architecture and regulation of the HIV-1 assembly and holding compartment in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Macrophage internal HIV-1 is protected from neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Epitope exposure on functional, oligomeric HIV-1 gp41 molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Preparation and characterization of human HIV type 1 neutralizing reference sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Crystallographic structure of an intact IgG1 monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Structural mechanism of trimeric HIV-1 envelope glycoprotein activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Dimeric association and segmental variability in the structure of human CD4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

UCSF Chimera--a visualization system for exploratory research and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Crystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design Implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.10.020

1 reference

29 August 2017

1 reference

PubMed ID

24140477